Author:
Bissett Sara L.,Wilkinson Dianna,Tettmar Kate I.,Jones Nicky,Stanford Elaine,Panicker Gitika,Faust Helena,Borrow Ray,Soldan Kate,Unger Elizabeth R.,Dillner Joakim,Minor Philip,Beddows Simon
Abstract
ABSTRACTSuitably controlled serosurveillance surveys are essential for evaluating human papillomavirus (HPV) immunization programs. A panel of plasma samples from 18-year-old females was assembled, the majority of the samples being from recipients of the bivalent HPV vaccine. Antibody specificities were evaluated by three independent laboratories, and 3 pools that displayed no antibodies to any HPV type tested or intermediate or high levels of antibody to HPV16, HPV18, HPV31, and HPV45 were created. These pools will be useful as control reagents for HPV serology.
Publisher
American Society for Microbiology
Subject
Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy
Reference21 articles.
1. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years;Brown;J. Infect. Dis.,2009
2. Generation of HPV pseudovirions using transfection and their use in neutralization assays;Buck;Methods Mol. Med.,2005
3. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine;Dessy;Hum. Vaccin.,2008
4. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18;Dias;Clin. Diagn. Lab Immunol.,2005
5. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera;Draper;Vaccine,2011
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献